HOME >> BIOLOGY >> NEWS
Antiviral From Advanced Viral Research Corp. Inhibits CCR5 Cell Receptor For HIV

Yonkers, NY, February 25, 1999 - Advanced Viral Research Corp. (OTC BB:ADVR) announced today that its scientists have discovered that its lead antiviral drug, Reticulose, inhibited the production of a key cellular receptor for HIV. Using CD4 positive T-lymphocytes, the scientists found that Reticulose markedly decreased the number of cellular CCR5 receptors. The CCR5 receptor is one of the three most important cell receptors needed by the AIDS virus, HIV, to attach to its target cells and initiate infection.

Interference with the function of the CCR5 cellular chemokine receptor is known to increase the resistance of T-lymphocytes and macrophages to HIV infection. A mutation in the CCR5 gene, especially prevalent in individuals of northern European descent, appears to render these individuals resistant to infection by HIV.

Commenting on this research, Dr. Shalom Z. Hirschman, President and CEO of Advanced Viral Research Corp., stated "The exciting discovery by our scientists that the immunomodulator, Reticulose, interferes with the production of the CCR5 receptor offers a novel approach to the development of therapeutic agents for HIV infection. This new finding may account, in part, for the beneficial effects of Reticulose in the treatment of HIV infected individuals observed in preliminary clinical trials. Furthermore, this new pathway of inhibiting HIV infection suggests that combination therapy with Reticulose may enhance the therapeutic effectiveness of the AIDS cocktails currently in use."

Reticulose is a peptide nucleic acid preparation produced by Advanced Viral Research Corp. which, based on previous history, has been show to be effective against a number of viral diseases. For further information, contact Mark Amster at 954-458-7636.


'"/>

Contact: William Bregman
advr@cwtel.com
954-458-7636
Advanced Viral Research Corp.
25-Feb-1999


Page: 1

Related biology news :

1. Research Findings Suggest Potent, Broad-Spectrum Antiviral Activity For Vertexs Investigational IMPDH Inhibitor VX-497
2. Phase III Results Suggest Potent Antiviral Activity For Vertex And Glaxo Wellcomes Second-Generation HIV Protease Inhibitor Agenerase TM
3. New Model Makes It Possible To Predict Emergence Of Antiviral Drug Resistance
4. Advanced sensors, computing systems tracking sea animals worldwide
5. Statement by the Ethics Advisory Board of Advanced Cell Technology, Inc.
6. UC Irvine Advanced Power and Energy Program awarded $3 million grant by California Energy Commission
7. X-ray crystallography at Advanced Photon Source
8. University of Washington partners with Advanced Tissue Sciences and others in $10 million grant to grow human heart tissue
9. Advanced cell technology reports reversal
10. Advanced light source reveals secrets of ribosome structure
11. Novel Drug Trial To Treat Advanced Prostate Cancer Enrolling Patients At UCSF/Mount Zion Cancer Center

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/27/2019)... ... August 27, 2019 , ... e3 Diagnostics, the nation’s ... it has partnered with Bertec, a leading manufacturer of force measurement devices for ... a full line of clinical systems for both assessment and treatment of balance ...
(Date:8/23/2019)... ... August 22, 2019 , ... R121 solidifies its place within ... of 2018. Along with the name change, this rebranding includes a comprehensive redesign ... create a cohesive brand that blended our core foundation of genuine ‘one-to-one’ relationships ...
(Date:8/15/2019)... LONDON (PRWEB) , ... August 15, 2019 , ... ... launch of their Food and Agriculture practice, a new unit dedicated to building 100 ... in sustainable nutrition, raw materials and supply chains. , Deep Science Ventures was ...
Breaking Biology News(10 mins):
(Date:8/14/2019)... ... August 13, 2019 , ... ... focus on prepackaged mobile phases for QC laboratories. After gaining a few significant ... laboratory sciences approach into a valued supplier of manufacturing processing solutions, including reagents ...
(Date:8/6/2019)... ... 2019 , ... Shoreline Biome, a microbiome research ... has announced partnerships with six international distributors. , The distributors will sell ... Australia, Benelux, Indonesia, Korea, Malaysia, Myanmar, New Zealand, Singapore, the United Kingdom, and ...
(Date:7/30/2019)... ... July 30, 2019 , ... ... building and cooking events company. Not only has the company already hosted many ... offering Private Cooking Parties to its guests. , With Lajollacooks4u’s Private Cooking Parties, ...
(Date:7/19/2019)... ... July 18, 2019 , ... World renowned ... be joining forces with California-based charity Coalition Duchenne for its 9th Annual Expedition ... raises awareness and funding for Duchenne muscular dystrophy and was founded by Sabahan ...
Breaking Biology Technology:
Cached News: